Literature DB >> 19843865

Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy.

Cindy Cavelier1, Christine Didier, Naïs Prade, Véronique Mansat-De Mas, Stéphane Manenti, Christian Recher, Cécile Demur, Bernard Ducommun.   

Abstract

Genomic instability in solid tumors participates in the oncogenetic process and is associated with the activation of the DNA damage response pathway. Here, we report the activation of the constitutive DNA damage and checkpoint pathway associated with complex karyotypes in samples from patients with acute myeloid leukemia (AML). We show that antagonizing CHK1 kinase with a small inhibitory compound or by RNA interference strongly reduces the clonogenic properties of high-DNA damage level AML samples, particularly those with complex karyotypes. Moreover, we observe a beneficial effect of CHK1 inhibition in high-DNA damage level AML samples treated with 1-beta-d-arabinofuranosylcytosine. In contrast, CHK1 inhibition has no effect on the clonogenic properties of normal hematopoietic progenitors. All together, our results indicate that CHK1 inhibition may represent an attractive therapeutic opportunity in AML with complex karyotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843865     DOI: 10.1158/0008-5472.CAN-09-0939

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.

Authors:  Kristina A Cole; Jonathan Huggins; Michael Laquaglia; Chase E Hulderman; Mike R Russell; Kristopher Bosse; Sharon J Diskin; Edward F Attiyeh; Rachel Sennett; Geoffrey Norris; Marci Laudenslager; Andrew C Wood; Patrick A Mayes; Jayanti Jagannathan; Cynthia Winter; Yael P Mosse; John M Maris
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 11.205

2.  CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Authors:  Leena Chaudhuri; Nicole D Vincelette; Brian D Koh; Ryan M Naylor; Karen S Flatten; Kevin L Peterson; Amanda McNally; Ivana Gojo; Judith E Karp; Ruben A Mesa; Lisa O Sproat; James M Bogenberger; Scott H Kaufmann; Raoul Tibes
Journal:  Haematologica       Date:  2013-10-31       Impact factor: 9.941

3.  RNAi screening of the kinome with cytarabine in leukemias.

Authors:  Raoul Tibes; James M Bogenberger; Leena Chaudhuri; R Tanner Hagelstrom; Donald Chow; Megan E Buechel; Irma M Gonzales; Tim Demuth; James Slack; Ruben A Mesa; Esteban Braggio; Hongwei H Yin; Shilpi Arora; David O Azorsa
Journal:  Blood       Date:  2012-01-20       Impact factor: 22.113

4.  Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance.

Authors:  Laure David; Stéphane Manenti; Christian Récher; Jean-Sébastien Hoffmann; Christine Didier
Journal:  Mol Cell Oncol       Date:  2017-09-18

5.  MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

Authors:  Silvia Maifrede; Esteban Martinez; Margaret Nieborowska-Skorska; Daniela Di Marcantonio; Michael Hulse; Bac Viet Le; Huaqing Zhao; Katarzyna Piwocka; Italo Tempera; Stephen M Sykes; Tomasz Skorski
Journal:  Blood Adv       Date:  2017-08-09

Review 6.  DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.

Authors:  Maria Teresa Esposito; Chi Wai Eric So
Journal:  Chromosoma       Date:  2014-08-12       Impact factor: 4.316

7.  Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia.

Authors:  L L Yuan; A S Green; S Bertoli; F Grimal; V Mansat-De Mas; C Dozier; J Tamburini; C Récher; C Didier; S Manenti
Journal:  Leukemia       Date:  2013-06-10       Impact factor: 11.528

8.  Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Authors:  Judith E Karp; Brian M Thomas; Jacqueline M Greer; Christopher Sorge; Steven D Gore; Keith W Pratz; B Douglas Smith; Karen S Flatten; Kevin Peterson; Paula Schneider; Karen Mackey; Tomoko Freshwater; Mark J Levis; Michael A McDevitt; Hetty E Carraway; Douglas E Gladstone; Margaret M Showel; Sabine Loechner; David A Parry; Jo Ann Horowitz; Randi Isaacs; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-10-23       Impact factor: 12.531

Review 9.  Roles of Chk1 in cell biology and cancer therapy.

Authors:  Youwei Zhang; Tony Hunter
Journal:  Int J Cancer       Date:  2013-05-28       Impact factor: 7.396

Review 10.  Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.

Authors:  Thomas P Matthews; Alan M Jones; Ian Collins
Journal:  Expert Opin Drug Discov       Date:  2013-04-18       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.